Trials / Completed
CompletedNCT02622932
Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to Investigate the Absorption, Metabolism and Excretion of \[14C\] Anlotinib in Patients With Advanced Cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib and 14C-labeled Anlotinib | oral |
Timeline
- Start date
- 2015-12-02
- Primary completion
- 2016-12-30
- Completion
- 2017-08-01
- First posted
- 2015-12-07
- Last updated
- 2019-04-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02622932. Inclusion in this directory is not an endorsement.